Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS formulation.


An ALZA OROS drug delivery system was evaluated for its potential to increase drug load and reduce side effects when used with RWJ-333369 (S-2-O-carbamoyl-1-o-chlorophenyl-ethanol), a novel neuromodulatory agent initially developed by SK Bio-Pharmaceuticals and licensed by Johnson & Johnson. RWJ-333369 was found to have two crystalline polymorphs (A and B… (More)
DOI: 10.1016/j.ijpharm.2008.08.049

5 Figures and Tables


  • Presentations referencing similar topics